

25. Adler AI, Stevens RJ, Neil HA, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). *Kidney Int* 2003; 63: 225-232.

26. Vijay V, Snehalatha C, Shima K, Lalitha S, Ramachandran A. Familial aggregation of diabetic kidney disease in Type 2 diabetes in South India. *Diab. Res. Clin. Pract.* 1999; 3: 167-171.

27. Krolewski AS. Genetics of diabetic nephropathy: Evidence for major and minor gene effects. *Kidney Int* 1999; 55: 1582-1596.

28. Kennon B, Petrie JR, Small M, Connell JM. Angiotensin-converting enzyme gene and diabetes mellitus. *Diabet Med* 1999; 60: 448-58.

29. Yoshida H, Kuriyama S, Atsumi Y, et al. Angiotensin I converting enzyme polymorphism in non-insulin dependent diabetes mellitus. *Kidney Int* 1996; 50: 657-64.

30. Doi Y, Yoshizumi H, Yoshinari M, et al. Association between a polymorphism in the angiotensin-converting enzyme gene and microvascular complications in Japanese patients with NIDDM. *Diabetologia* 1996; 39: 97-102.

31. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001; 414: 813-20.

32. Gnudi L, Gruden G. Pathogenesis of diabetic nephropathy. In: Pickup JC, Williams G, eds. *Textbook of diabetes*. 3rd Ed. Oxford: Blackwell Science Ltd, 2003, pp. 52.1-22.

33. Kimmelstiel P, Wilson C. Inter-capillary lesions in the glomeruli of kidney. *Am J Pathol* 1936; 12: 83-97.

34. Mauer SM, Steffes MW, Brown DM. The kidney in diabetes. *Am J Med* 1981; 70: 603-12.

35. American Diabetes Association: Nephropathy in diabetes (Position Statement). *Diabetes Care* 2004; 27 (Suppl 1): S79- S83.

36. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Int Med* 2003; 139: 137-147.

37. Rossing P, Rossing K, Gaede P, Pedersen O, Parving HH. Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. *Diabetes Care* 2006; 29: 1024-1030.

38. Premalatha G, Vidhya K, Deepa R, Ravikumar R, Rema M, Mohan V. Prevalence of non-diabetic renal disease in type 2 diabetic patients in a diabetes centre in southern India. *J Assoc Phys India* 2002; 50: 1135-1139.

39. Tuomilehto J, Lindstrom J, Eriksson J, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. *N Eng J Med* 2001; 344: 1343-50.

40. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle modification or metformin. *N Eng J Med* 2002; 346: 393-403.

41. Li G, Hu Y, Yang W, et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. *Diabet Res Clin Pract* 2002; 58: 193-200.

42. Azen SP, Peters RK, Berkowitz K, et al. TRIPOD (Troglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. *Control Clin Trials* 1998; 19: 217-231.

43. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. *Lancet* 2002; 359: 2072-2077.

44. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; 329: 977-86.

45. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; 352: 837-53..

46. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care* 2000; 23(Suppl. 2): B21-B29.

47. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. *JAMA* 2003; 290:2159-2167.

48. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. *Diabetes Care* 1994; 17: 1247-51.

49. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003; 289: 2560-72.

50. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. *Diabetes Care* 2003; 26: 886-91.

51. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. *J Intern Med* 2003; 254: 45-66.

52. Viberti G, Wheelton NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation* 2002; 106: 672-678.

53. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. *BMJ* 2000; 321: 1440-1444.

54. Jacobsen P, Rossing K, Parving HH. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. *Curr Opin Nephrol Hypertens* 2004; 13: 319-324.

55. Hovind P, Rossing P, Tarnow L, et al. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. *Kidney Int* 2001; 60: 277-283.

56. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. *Arch Intern Med* 2003; 161: 2661-2667.

57. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal diseases: a meta-analysis. *Ann Intern Med* 1996; 124: 627-632.

58. Gross JL, Zelmanovitz T, Moulin CC, et al. Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomised crossover trial. *Diabetes Care* 2002; 25: 645-651.

59. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. *Diabetes* 2003; 52: 2110-2120.

60. Kelly DJ, Zhang Y, Hepper C, et al. Protein kinase C  $\alpha$  inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. *Diabetes* 2003; 52: 512-518.

61. Bolton WK, Catran DC, Williams ME, et al. Randomised trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. *Am J Nephrol* 2004; 24: 32-40.

62. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. *Hypertension* 2003; 41:64-68.

63. Epstein M, Buckalew V, et al. Antiproteinuric efficacy of eplerone, enalapril and eplerone/enalapril combination in diabetic hypertensives with microalbuminuria. *Am J Hypertens* 2002; 15: 24A.

**Conference News**

**13<sup>th</sup> ANNUAL INTERNATIONAL CONFERENCE of INDIAN ACADEMY OF ECHOCARDIOGRAPHY** will be on **February 8 -10 , 2008 at Ashoka Hotel, New Delhi (India)**

**SCIENTIFIC HIGHLIGHTS OF CONFERENCE**

Stress on clinical echocardiography with emphasis on role in management issues; Lectures to cater to all levels of echocardiographers & cardiologists; Meet the expert sessions with active interaction with faculty; Interesting live workshops; Daily sessions on interesting case studies; Young Investigator award session; Orations of general interest for participants; **Natesa G Pandian Gold Medal For Best Case Presenter:** (a) The award is applicable to members of IAE (b) age of the presenter must be below 45 years (c) presentation time will be 8 mins (d) the relevant CD containing brief history, relevant investigations, well edited echo images and final diagnosis must be sent to HQ, IAE by 30 November, 2007. (e) 10 best cases will be selected and the presenters will be informed by 31<sup>st</sup> December, 2007; Free paper sessions will be encouraged; An excellent scientific program of practical importance will be presented;

Organizing Chairman	Org. Secretary	Secretary	Scientific Chairman	Scientific Chairman	Adviser, Scientific Program
S.K. Parashar	Rakesh Gupta	Sameer Shrivastava	H.K. Chopra	R.R. Kasliwal	J.C. Mohan
9810146231	9811013246	9810154522	9811090204	981002512	9811061392

*For further details contact :*

**Dr.Rakesh Gupta/ Dr.Sameer Shrivastava IAE Headquarter: Echo and Color Doppler Centre, Jrop Healthcare, C1/16, Ashok Vihar, Delhi – 110057, PH : 011-2741-5646, 2713 – 4839, Mob : 9811013246, E-mail : jrop2001@yahoo.com, jrop2001@gmail.com Website: www.iaecho.org**

**Conference News**

**South Zonal Conference of Medical Microbiologists, SOZOCON - MICRO : 2008** will be held on 20<sup>th</sup> January, 2008 at Puducherry organized by Sri Manakula Vinayagar Medical College and Hospital, Madagadipet, Puducherry and Indian Association of Medical Microbiologists, Tamil Nadu - Puducherry IAMM Chapter .

**Dr. J. Shanmugam**  
Chairman, SOZOCON - Micro: 2008